Cardiogenic Pulmonary Edema Clinical Trial
Official title:
Effect of Continuous Positive Airway Pressure as a First Line Therapy in Out-of-Hospital Management of Severe Cardiogenic Pulmonary Edema
In cardiogenic pulmonary edema, Continuous Positive Airway Pressure (CPAP) added to medical treatment improves outcome. The present study was designed to assess the benefit of CPAP as a first line treatment of cardiogenic pulmonary edema in the out-of-hospital environment.
Cardiogenic pulmonary edema (CPE) is a frequent presenting process for acute out-of-hospital
practice. Acute left heart failure may occur from a variety of processes that rapidly
deteriorates to this generalized cardiopulmonary disorder. The classical treatment of
out-of-hospital CPE includes supplemental oxygen, vasodilators, loop diuretics, and
morphine. If not effective, or because of the associated respiratory depression, tracheal
intubation and mechanical ventilation are often needed, which, by themselves are associated
with a worse prognosis. Continuous positive airway pressure (CPAP) has been proposed as an
alternative to mechanical ventilation in CPE. This technique not only improves alveolar
recruitment and decreases the work of breathing 4 but also reduces left ventricular
afterload, and both right and left ventricular preload. The overall effect of CPAP in the
acute management of CPE is to improve cardio-respiratory function and sustained tissue
oxygenation. Furthermore, the combination of CPAP with medical treatment in patients with
CPE significantly reduces the need for intubation and improves the outcome.
Unfortunately, very limited data are available on the effects of CPAP in the out-of-hospital
practice. Thus, we tested the potential benefit of immediate use of CPAP alone in comparison
with pharmacological therapy in treatment of CPE in the acute out-of-hospital environment.
The protocol lasts 45 minutes, divided into 3 periods of 15 minutes. Patients with severe
pulmonary edema are randomly assigned in 2 groups: 1/ “Early CPAP” (n=63): CPAP alone
(T0-T15); CPAP + medical treatment (T15-T30); medical treatment alone (T30-T45); 2/ “Late
CPAP” (n=61): medical treatment alone (T0-T15); medical treatment + CPAP (T15-T30); medical
treatment alone (T30-T45). Primary endpoint : effect of early CPAP on a dyspnea clinical
score and on arterial blood gases. Secondary endpoints : incidence of tracheal intubation,
inotropic support, and in-hospital mortality.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04971213 -
HIgh Flow Versus NIV for Acute Cardiogenic PuLmonary Oedema With Acute Respiratory Failure in an ED
|
N/A | |
Completed |
NCT01680783 -
Non-Invasive Ventilation Via a Helmet Device for Patients Respiratory Failure
|
N/A | |
Completed |
NCT00785174 -
Non-Invasive Ventilation Versus Continuous Positive Airway Pressure in Cardiogenic Pulmonary Edema: a Multicentre Study
|
Phase 3 | |
Completed |
NCT04005092 -
Helmet CPAP Versus HFNC in Acute Cardiogenic Pulmonary Edema
|
N/A | |
Recruiting |
NCT06107257 -
Cardiogenic Acute Pulmonary Edema in Subjects Over 75 Years Old: Impact of Non-invasive Ventilation on Mortality
|
||
Completed |
NCT03041428 -
Ultra Protective Ventilation During Venoarterial Extracorporeal Membrane Oxygenation (UPV-ECMO)
|
N/A |